Vienna-Based Company Cutanos Wins Barda Vital Prize Challenge for Innovative Vaccine Technology

Cutanos GmbH, a biotechnology company based in Vienna, Austria, was awarded 1st place in the BARDA VITAL Prize (BVP) Challenge, endowed with USD 20,000 by the BARDA Accelerator Network (BAN), at the BARDA VITAL Symposium in Berlin, Germany.

Established by the Biomedical Advanced Research and Development Authority (BARDA), part of the HHS Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS), the BARDA Accelerator Network (BAN) fosters the growth of health security innovation ecosystems globally and accelerates the development and commercialization of next-generation health security solutions. The BARDA VITAL Prize Challenge awards innovative startups and their groundbreaking solutions to potentially make a significant impact on public health.

Cutanos is dedicated to developing next-generation vaccines incorporating its proprietary Langerhans Cell Targeting (LC-TDS) Technology. Looking ahead, the company will increase its efforts towards infectious diseases, capitalizing on the advantages of its technology to boost the efficacy and stability of mRNA vaccines, as well as high patient compliance due to pain-free skin administration. 

"We are incredibly honored to receive this recognition from BARDA," said Robert Wawrzinek, CEO of Cutanos. "This award validates our commitment to develop innovative vaccine technologies that can make a real difference in the fight against infectious diseases. We believe that minimally invasive vaccination will improve vaccine acceptance and accessibility worldwide." 

About Cutanos:

Cutanos GmbH is a biotech company founded in 2021 focusing on antigen-specific vaccines against infectious diseases and cancer. Cutanos uses a modular drug delivery system specifically targeting immune cells in the skin. The Max Planck Society spin-off operates from its headquarters in Vienna, financially backed by an Austrian/German investment consortium, including KHAN Technology Transfer Fund I, xista science ventures and HTGF | High-Tech Gründerfonds-Tech Gründerfonds, as well as public grants from the Austria Wirtschaftsservice and FFG Austrian Research Promotion Agency

More information:

Biomedical Advanced Research and Development Authority (BARDA) 


Barda Vital Prize: 

Media Contact:

Robert Wawrzinek

The sender takes full responsibility for the content of this news item. Content may include forward-looking statements which, at the time they were made, were based on expectations of future events. Readers are cautioned not to rely on these forward-looking statements.

As a life sciences organization based in Vienna, would you like us to promote your news and events? If so, please send your contributions to news(at)